High ORR with sequential regimen in CLL

Micrograph showing CLL
A sequential treatment regimen can produce a high overall response rate (ORR) in patients with treatment-naïve (TN) or relapsed/refractory (RR) chronic lymphocytic leukemia (CLL), results of the CLL2-BAG study suggest. Patients who received bendamustine followed by obinutuzumab and venetoclax achieved an ORR of 95%, and 87% of them were negative... [Read Article]

CHMP recommends new indication for obinutuzumab

Micrograph showing FL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for obinutuzumab (Gazyvaro). The new proposed indication is for obinutuzumab in combination with chemotherapy for patients with previously untreated, advanced follicular lymphoma (FL). This would be followed by obinutuzumab maintenance in patients... [Read Article]

CAR T-cell therapy ‘highly effective’ in high-risk CLL

Cameron Turtle, MBBS, PhD
Photo by Robert Hood,
Fred Hutchinson Cancer
Research Center
A chimeric antigen receptor (CAR) T-cell therapy is “highly effective” in high-risk patients with chronic lymphocytic leukemia (CLL), according to researchers. The CD19 CAR T-cell therapy, JCAR014, produced an overall response rate of 71% and a complete response (CR) rate... [Read Article]

GAD-M produces high ORR in treatment-naïve ENKTL

14th International Conference
on Malignant Lymphoma
A 4-drug regimen has demonstrated efficacy in a phase 2 trial of patients with treatment-naïve extranodal natural killer/T-cell lymphoma (ENKTL). Treatment with gemcitabine, PEG-asparaginase, dexamethasone, and methotrexate (GAD-M) produced a 94% overall response rate (ORR) and an 83% complete response (CR) rate in this trial. Responses and... [Read Article]

PD-1 inhibitors treat resistant gray zone lymphoma

Doctor evaluating patient
Photo courtesy of the CDC
Three case reports published in The New England Journal of Medicine describe the successful use of PD-1 inhibitors in gray zone lymphoma. Two patients who had failed treatment with DA-EPOCH-R (dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab) ultimately responded to treatment with pembrolizumab.... [Read Article]

Common insurance plans exclude NCI, NCCN cancer centers

Cancer patient
receiving chemotherapy
Photo by Rhoda Baer
Narrow insurance plan coverage may prevent US cancer patients from receiving care at “high-quality” cancer centers, according to research published in the Journal of Clinical Oncology. Researchers found that “narrow network” insurance plans—lower-premium plans with reduced access to certain providers—are more likely to exclude doctors associated... [Read Article]